23 reports

MARKET ##.

  • Heart Failure
  • Europe
  • Japan
  • United States
  • World
  • Aetiologies of Heart Failure

REFERENCES ##.

  • Cardiovascular Disease
  • Chronic Disease
  • Heart Failure
  • Pathology
  • HEART FAILURE THERAPEUTICS MARKET, ETIOLOGIES OF HF

STEM CELL REPORTS; ##(##): ##-## ##(##): ##-## ##(##): ##-## IN CARDIOLOGY (JCARE-CARD).

  • Heart Failure
  • World
  • Market Size
  • Bristol-Myers Squibb Company
  • Les Laboratoires Servier SAS

Net sales in 2015 decreased ##% compared to 2014.

  • Heart Failure
  • HeartWare International, Inc.
  • Jude Medical, Inc.
  • ReliantHeart
  • Thoratec Corporation

As a result, certain genetic polymorphisms, drugs, and diet can interfere with this process (Holmberg et al., 2014).

  • Heart Failure
  • United States
  • AstraZeneca PLC
  • NSTEMI group
  • The Medicines Company

Drivers and their Impact Impact on Key End-user Category Hospitals Driver Pharmaceutical Stores Low Low ## ## ## ## ## High High Increase in Elderly Population Unmet Medical Needs Growing Sedentary Lifestyle Promising Drug Pipeline Driver Increase in Elderly Population Low Low ## ## ## ## ##

  • Heart Failure
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc

One unit refers to one single chamber pacemaker.

  • Cardiac Management
  • Clinical Trial
  • Heart Failure
  • Medical Device
  • GlobalData's company
  • PROGNOSTIC MIRNA ASSAY - HEART FAILURE - PRODUCT STATUS

Summary Firalis SAS (Firalis) is a biotechnology company that develops biomarkers and biomarker-based diagnostic kits.The company’s biomarker products comprise recombinant proteins and calibrants, Elisa kits, and monoclonal antibodies, among others. It offers biomarker services such as flow cytometry, metabolomics...

  • Biomarker
  • Chronic Disease
  • Heart Failure
  • Immunochemistry Test
  • Firalis SAS

In May 2016, Kristie Holmes, ##, called ##-##-## due to shortness of breath and weakness while driving her three children to school.

  • Heart Attack
  • Heart Failure
  • United States
  • Product Initiative
  • Abiomed, Inc.
  • Clinical Trial profile. 55 Trial Title
  • Clinical Trial profile. 589 Trial Title

## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## United Kingdom Source

  • Acute Coronary Syndrome
  • Clinical Trial
  • Heart Failure
  • World
  • AstraZeneca PLC

The company' s product portfolio includes technologies for mass spectrometry, electron microscopy, genetic sequencing, protein and molecular biology research.

  • Diagnostics
  • Heart Failure
  • In Vitro Diagnostic Reagent
  • United States
  • bioMerieux S.A.

THE MOLECULES DEVELOPED BY COMPANIES IN PRE-REGISTRATION, PHASE III, PHASE II, PHASE I, PRECLINICAL AND DISCOVERY STAGES ARE ##, ##, ##, ##, ## AND ## RESPECTIVELY.

  • Cardiology
  • Heart Failure
  • United States
  • Product Initiative
  • Bayer AG
  • Clinical Trial profile. 33 Trial Title
  • Clinical Trial profile. 581 Trial Title

DalCor secured a worldwide exclusive license for dalcetrapib together with rights to the genetic marker for use with dalcetrapib and all other CETP inhibitors.

  • Acute Coronary Syndrome
  • Clinical Trial
  • Heart Failure
  • Pharmaceutical
  • World
  • CELL THERAPY FOR HEART FAILURE - DRUG PROFILE
  • AND GROWING PROBLEM AMONG RENAL PATIENTS WORLDWIDE.

THE DRUG CANDIDATE IS A GENETICALLY ENGINEERED RECOMBINANT PEPTIDE FRAGMENT OF NEUREGULIN-## (BETA##A ISOFORM).

  • Cardiovascular Disease
  • Cell Therapy
  • Heart Failure
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Heart Failure
  • World
  • Product Initiative
  • STEM CELL THERAPY FOR HEART FAILURE
  • R&D Progress

NEUCARDIN IS A GENETICALLY ENGINEERED RECOMBINANT PEPTIDE FRAGMENT OF NEUREGULIN-## (BETA##A ISOFORM).

  • Gene Therapy
  • Heart Failure
  • United States
  • Company
  • Product Initiative
  • Clinical Trial profile. 889 Trial Title
  • 5. All the trials included are unique trials.

Approximately ## patients were randomized ##:##:##:## to receive placebo or ## of ## oral formulations twice daily (BID) (M-F##, M-F##, and SCT-F##) for ## days in each of two cohorts (## mg BID Cohort ## mg BID Cohort ##).

  • Cardiovascular Disease
  • Chronic Disease
  • Clinical Trial
  • Heart Failure
  • World

Nov ##, 2015 Jul ##, 2015 group, placebo-controlled study to evaluate the efficacy and safety of CER-## on APOA-## and vessel wall area in patients with genetically defined familial primary hypoalphalipoproteinemia and receiving background optimized lipid therapy.

  • Acute Coronary Syndrome
  • Cardiovascular Disease
  • Heart Failure
  • Research And Development
  • Bayer AG

University of Utah undertakes research on animal subjects, radiation and laboratory safety, resource for genetic and epidemiologic research, and others.

  • Clinical Trial
  • Heart Failure
  • Hospital
  • Interventional Cardiology Device
  • Medtronic, Inc.
  • FEATURED NEWS & PRESS RELEASES

The drug candidate is a genetic fusion product, where VPAC##-selective vasoactive intestinal peptide (VIP) has been genetically engineered using the elastinlike biopolymer (ELP).

  • Heart Failure
  • Therapy
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Heart Failure
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 1196 Trial Title

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Heart Failure
  • World

The drug candidate is a genetic fusion product, where VPAC##-selective vasoactive intestinal peptide (VIP) has been genetically engineered using the elastin-like biopolymer (ELP).

  • Heart Failure
  • Research And Development
  • United States
  • Company Operations
  • Product Initiative